Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-P3 PET/CT Imaging of PSMA in Malignant Tumors
NCT05887687Recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-P3 in Neoplasm, sponsored by Peking University First Hospital. Primary endpoints: Diagnostic efficacy of 68Ga-P3 PET/CT at 1 year and Detection efficacy of 68Ga-P3 PET/CT at 1 year. Started May 2023; status: recruiting.
02
Drugs
68Ga-P3
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT05887687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887687.